Strategic Wealth Partners Ltd. Has $269,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Strategic Wealth Partners Ltd. cut its holdings in Bristol-Myers Squibb (NYSE:BMY) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,205 shares of the biopharmaceutical company’s stock after selling 211 shares during the quarter. Strategic Wealth Partners Ltd.’s holdings in Bristol-Myers Squibb were worth $269,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. ESL Trust Services LLC bought a new position in Bristol-Myers Squibb during the first quarter worth $27,000. LGT Financial Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 42.7% in the 2nd quarter. LGT Financial Advisors LLC now owns 759 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 227 shares during the period. MFA Wealth Advisors LLC bought a new stake in Bristol-Myers Squibb in the 2nd quarter valued at about $39,000. Fairman Group LLC acquired a new position in Bristol-Myers Squibb during the 4th quarter worth approximately $42,000. Finally, Beach Investment Counsel Inc. PA bought a new position in Bristol-Myers Squibb in the second quarter worth approximately $42,000. 76.41% of the stock is currently owned by institutional investors.

Bristol-Myers Squibb Trading Down 0.7 %

NYSE BMY opened at $52.41 on Friday. The stock has a market capitalization of $106.24 billion, a price-to-earnings ratio of -16.91, a PEG ratio of 12.96 and a beta of 0.46. The business’s fifty day moving average is $49.60 and its 200-day moving average is $46.39. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $57.65.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The firm had revenue of $12.20 billion for the quarter, compared to analysts’ expectations of $11.54 billion. During the same period in the previous year, the company earned $1.75 earnings per share. The company’s quarterly revenue was up 8.7% on a year-over-year basis. Equities research analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 4.58%. The ex-dividend date is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BMY. Deutsche Bank Aktiengesellschaft lowered their target price on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Barclays upped their price objective on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a report on Monday. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Monday, July 29th. TD Cowen upped their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the stock a “hold” rating in a report on Monday. Finally, UBS Group lifted their price target on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, one has given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $53.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.